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Background: The optimal surgical management of patients found to have unresectable pancreatic
cancer at open exploration remains unknown.
Methods: Records of patients who underwent non-therapeutic laparotomy for pancreatic cancer during
2000–2009 and were followed until death at Memorial Sloan–Kettering Cancer Center, New York, were
reviewed.
Results: Over the 10-year study period, 157 patients underwent non-therapeutic laparotomy. Laparo-
tomy alone was performed in 21% of patients; duodenal bypass, biliary bypass and double bypass were
performed in 11%, 30% and 38% of patients, respectively. Complications occurred in 44 (28%) patients.
Three (2%) patients died perioperatively. Postoperative interventions were required in 72 (46%) patients
following exploration. The median number of inpatient days prior to death was 16 (interquartile range:
8–32 days). Proportions of patients requiring interventions were similar regardless of the procedure
performed at the initial operation, as were the total number of inpatient days prior to death. Patients
undergoing gastrojejunostomy required fewer postoperative duodenal stents and those undergoing
operative biliary drainage required fewer postoperative biliary stents.
Conclusions: In this study, duodenal, biliary and double bypasses in unresectable patients were not
associated with fewer invasive procedures following non-therapeutic laparotomy and did not appear to
reduce the total number of inpatient hospital days prior to death. Continued effort to identify unresect-
ability prior to operation is justified.
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Introduction
Pancreatic cancer remains a lethal malignancy. The majority of
patients present with metastatic disease in which survival
is measured in months. Resection of pancreatic cancer by
pancreaticoduodenectomy is favoured in patients who present
with radiographically localized disease as this treatment in com-
bination with systemic therapy provides the only chance for long-
term survival.
Despite improvements in preoperative assessment, many
patients with pancreatic cancer are unresectable at the time of
laparotomy. Non-therapeutic laparotomy has been associated
with significant morbidity, a decreased likelihood of receiving
systemic treatment, and diminished quality of life.1,2 Several
pre-emptive or palliative procedures have been advocated in
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unresectable patients at the time of non-therapeutic laparotomy.
These procedures include biliary bypass and duodenal bypass
(gastrojejunostomy) to prevent biliary and duodenal obstruction,
respectively, and coeliac plexus block to decrease or prevent pain.
Proponents of prophylactic operative bypass report that 75% of
patients with unresectable periampullary malignancy will develop
biliary obstruction and 25% will develop gastric outlet obstruc-
tion (GOO) prior to death.3,4 However, critics of this strategy have
reported that 97% of unresectable patients who do not receive a
surgical bypass can be effectively palliated without an operation,
particularly now that endoscopic biliary and duodenal stenting
have become more effective.5 Thus, the optimal surgical strategy
for patients found to be unresectable at the time of exploration
remains unclear.
The current study sought to evaluate outcomes in patients with
unresectable disease at laparotomy, and to determine the efficacy
of biliary, duodenal or double bypass operations. These patients
were analysed to determine the number of subsequent invasive
procedures they required following exploration and the total
number of hospital days they accrued prior to death.
Materials and methods
Under a waiver of authorization from the Memorial Sloan–
KetteringCancerCenter (MSKCC) Institutional ReviewBoard, the
MSKCCprospectivepancreatic cancerdatabasewas retrospectively
reviewed to identify all patients who underwent non-therapeutic
laparotomy for periampullary carcinoma during 2000–2009. The
majority of these patients (93%) underwent laparotomy for pan-
creatic adenocarcinoma. Only patients who had been followed
until death at this institution were included for analysis.
Patients who had undergone non-therapeutic laparotomy were
denoted as having had one of four different procedures: explor-
atory laparotomy; duodenal bypass; biliary bypass, or double
bypass. Exploratory laparotomy was defined as an exploration
followed by closure without the performance of any surgical
bypass procedure(s). Duodenal bypass was defined as a gastroje-
junostomy at operation. Biliary bypass was defined as a sur-
gical biliary drainage procedure including hepaticojejunostomy,
choledochojejunostomy, hepatico- or choledochoduodenostomy,
and cholecystojejunostomy. Double bypass was defined as both a
duodenal and a biliary bypass. Postoperative procedures included
any surgical, endoscopic, percutaneous or interventional radiol-
ogy intervention that took place following the initial procedure in
order to manage a complication associated with the procedure or
to intervene in the context of new obstructive symptoms.
Perioperative events were defined as those occurring within
30 days of laparotomy. Perioperative complications were graded
according to an institutional system that has been previously
reported.6 Categorical variables were compared using Fisher’s
exact test. Continuous variables were evaluated using a Student’s
t-test or analysis of variance (anova) according to the number of
comparisons.
Results
During 2000–2009, 1286 patients were explored for potentially
resectable periampullary tumours. All patients underwent explo-
ration with the intent of curative resection. This group included
157 (12%) patients who were designated as unresectable at laparo-
tomy andwere followed at the study institution until death. Patient
characteristics according to the procedures performed are pre-
sented in Table 1. Diagnostic laparoscopy was performed in 109
patients (69%) prior to non-therapeutic laparotomy. Reasons for
unresectability were local invasion in 113 (72%) patients, meta-
static disease to the liver in 35 (22%) patients, peritoneal disease in
six (4%), and both or other causes in three (2%) patients. Having
been categorized as unresectable at exploration, 33 (21%) patients
underwent no further procedure (laparotomy). Duodenal bypass
was performed in 17 (11%) patients; 47 (30%) patients underwent
biliary bypass and 60 (38%) underwent double bypass (Fig. 1).
Biliary drainage was performed in 63 patients prior to explora-
tion (via endoluminal catheter or stent in 61 patients and via
operative drainage in two patients). Preoperative biliary drainage
did not influence intraoperative management of the biliary tree:
43 of the 63 patients (68%) who underwent preoperative drainage
also underwent either biliary or double bypass, and 64 of the
94 patients (68%) who did not undergo preoperative drainage
Table 1 Preoperative characteristics in the study cohort
All patients Laparotomy
patients
Duodenal bypass
patients
Biliary bypass
patients
Double bypass
patients
(n = 157) (n = 33) (n = 17) (n = 47) (n = 60)
Age, years, mean 67 69 66 66 65
Male gender, n (%) 87 (55) 21 (63) 5 (29) 28 (60) 33 (55)
Site of primary (HoP), n (%) 141 (93) 31 (97) 16 (94) 42 (93) 52 (91)
Preoperative nausea/vomiting, n (%) 23 (15) 0 9 (53) 4 (8) 10 (16)
Preoperative bilirubin, mg/dl, mean 4.5 2.1 1.0 6.4 5.4
Prior biliary drainage 63 (40) 14 (42) 6 (35) 17 (36) 26 (43)
M1 disease at laparotomy, n (%) 44 (28) 9 (27) 5 (29) 13 (27) 17 (28)
HoP, head of the pancreas.
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underwent operative biliary bypass (Table 1). Elevation of preop-
erative bilirubin was associated with the performance of biliary
bypass as 52 of 56 patients (93%) with bilirubin levels of
3 mg/dl underwent either a biliary or a double bypass proce-
dure, whereas only 55 of 100 patients (55%) with bilirubin levels
of <3 mg/dl did so (P < 0.001). Patients with preoperative nausea
and vomiting were more likely to undergo a gastrojejunostomy
(duodenal or double bypass) at surgery than patients without
nausea and vomiting [20 of 25 (80%) patients vs. 57 of 132 (43%)
patients; P < 0.01] (Table 2).
Non-surgical therapy (chemotherapy or radiation therapy) was
given to 114 (73%) patients following surgery (Table 3). Median
overall survival (OS) in all patients was 11 months [interquartile
range (IQR): 5–21 months] (Fig. 2). This did not differ signifi-
cantly amongst surgical groups.
Following exploration, 72 (46%) patients collectively under-
went 212 additional disease-related procedures. For 15 of these
patients (15/157, 10%), the postoperative procedure was another
operation. Within this group, six patients, representing 8% of
patients who did not undergo duodenal bypass at the initial
operation, underwent duodenal bypass for GOO. The remaining
nine operations were performed to address additional complica-
tions of disease other than biliary or duodenal obstruction. Endo-
scopic procedures (n = 106) were undertaken in 42 (27%) patients
Laparotomy
n = 33
Duodenal bypass
n = 17
Biliary bypass
n = 47
Double bypass
n = 60
GOO
28% 
(13/47)
GOO
0% 
(0/17)
GOO
30%
(10/33)
GOO
2% 
(1/60)
Biliary
obstruction
5% (3/60)
Biliary
obstruction
2% (1/47)
Biliary
obstruction
29% (5/17)
Biliary
obstruction
39% (13/33)
Complications
0% (0/33)
Complications
6% (1/17) 
Complications
13% (6/47)
Complications
15% (9/60)
Non-therapeutic laparotomy
Patients = 157
Figure 1 Procedures and outcomes in 157 patients undergoing non-therapeutic laparotomy for pancreatic cancer. GOO, gastric outlet
obstruction
Table 2 Patients with postoperative procedures based on preoperative symptoms
Indication No nausea/vomiting Nausea/vomiting No jaundice Jaundice
No GJ GJa No GJ GJa No BD BDb No BD BDb
(n = 75) (n = 57) (n = 5) (n = 20) (n = 39) (n = 34) (n = 10) (n = 73)
Gastric outlet obstruction, n 23 1 0 0 7 4 3 10
Biliary obstruction, n 14 7 0 1 12 0 6 4
Complications, n 5 8 1 2 0 5 1 10
aIncludes patients who had a duodenal bypass and patients who had a double bypass.
bIncludes patients who had a biliary bypass and patients who had a double bypass.
GJ, gastrojejunostomy; BD, biliary drainage.
Table 3 Postoperative chemotherapy and radiation therapy in the study cohort
All patients Laparotomy
patients
Duodenal bypass
patients
Biliary bypass
patients
Double bypass
patients
(n = 114) (n = 27) (n = 13) (n = 32) (n = 42)
Chemotherapy, n 57 15 (45) 8 (47) 14 (30) 20 (33)
Radiation, n 1 0 0 1 (2) 0
Chemoradiation, n 56 12 (36) 5 (29) 17 (36) 22 (36)
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following exploration. These included upper endoscopy (n = 33),
duodenal stenting (n = 21), endoscopic retrograde cholangiopan-
creatography with (n = 7) and without (n = 27) stent placement or
exchange, percutaneous endoscopic gastrostomy tube placement
(n = 15), duodenal dilation (n = 1), bronchoscopy (n = 1) and
colonoscopy (n = 1). Percutaneous procedures (n = 50) were per-
formed in 30 (19%) patients following exploration. These
included biliary drainage procedures (n = 32), drainage of abscess
(n = 16) and caval filter placement for deep venous thrombosis
(n = 2).
Complications occurred in 44 (28%) patients. Although most
complications were minor (Grades I and II), Grade III compli-
cations (requiring procedures) were more frequent following
biliary and double bypass surgery [15/107 (14%) in biliary and
double bypass patients vs. 1/50 (2%) in laparotomy and duode-
nal bypass patients (P < 0.02)]. Three (2%) perioperative deaths
occurred following biliary (n = 1) and double bypass (n = 2)
procedures.
There were no differences according to type of initial surgery in
the proportions of patients who required postoperative inter-
ventions: 55% of non-therapeutic laparotomy patients, 35% of
duodenal bypass patients, 51% of biliary bypass patients and 40%
of double bypass patients required further intervention (Table 4).
Of the 33 patients who underwent laparotomy only at explora-
tion, 18 (55%) required postoperative interventions (36 proce-
dures in total). These included procedures for GOO in 10 patients
(30%) and biliary obstruction in 13 (39%) patients. No patient
underwent any procedure to address surgical complications.Addi-
tional procedures (57 procedures in total) following duodenal
bypass were performed in six of 17 (35%) patients. No patient
required an additional procedure for GOO. Biliary drainage pro-
cedures were performed in five patients and one (6%) patient
required a procedure for complications of the original duodenal
bypass. Additional procedures (48 procedures in total) were
performed in 24 (51%) of the 47 patients who underwent a biliary
bypass. A single (2%) patient required an additional procedure for
biliary drainage and 13 (28%) patients underwent procedures for
GOO. Procedures to address surgical complications associated
with the original biliary bypass were required in six (13%)
patients. Following double bypass, 24 of 60 (40%) patients under-
went additional procedures (n = 71). Biliary or duodenal drainage
procedures were required in four patients (one for GOO; three for
biliary drainage). Procedures to address surgical complications
from the original double bypass were required in nine (15%)
patients.
Although there were no differences in the total number of post-
operative interventions performed in each group of patients, the
indications for these procedures varied according to the proce-
dures performed at exploration (Table 4). Fewer patients needed
interventions for GOO following a gastrojejunostomy: 1% of
duodenal and double bypass patients, and 29% of laparotomy and
biliary bypass patients required such an intervention (P < 0.001).
Likewise, fewer patients needed interventions for biliary obstruc-
tion after surgical biliary drainage: 4% of biliary and double
bypass patients, and 36% of laparotomy and duodenal bypass
patients required such an intervention (P < 0.01). Procedures for
complications were more common following biliary and double
bypass (14% of biliary and double bypass patients, and 2% of
laparotomy and duodenal bypass patients required such an inter-
vention), except amongst patients in whom biliary stents had been
placed preoperatively [two of 43 (5%) patients who underwent
operative biliary drainage after preoperative drainage vs. 13 of 64
(20%) patients who had operative biliary drainage without pre-
operative drainage (P < 0.02)] (Table 5).
Following discharge, 91 patients (58%) were readmitted to the
hospital. Readmission was required in 54% of patients who had
undergone exploratory laparotomy, 82% of patients who had a
duodenal bypass, 63% following biliary bypass, and 48% after
double bypass. Themedian number of days spent in hospital prior
to death in all patients was 16 (IQR: 8–32 days); this did not differ
according to the procedure performed at exploration [laparo-
tomy: 16 days; duodenal bypass: 12 days; biliary bypass: 18 days;
double bypass: 16 days (P = not significant)].
Discussion
Improvements in cross-sectional imaging over the past 20 years
have enhanced the ability to select patients with pancreatic
cancer suitable for resection. Preoperative staging with multide-
tector computed tomography imaging can determine resectabil-
ity with sensitivity and specificity that exceed 85%.7 The use
of laparoscopy may further identify another 8–17% of patients
with subradiologic metastatic disease.8 Thus, current imaging
and laparoscopic techniques enable the avoidance of unnecessary
laparotomy with greater frequency than in the past. Despite
these improvements, however, a subset of patients still undergo
laparotomy only to be deemed unresectable when the abdomen
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Figure 2 Overall survival in 157 patients undergoing non-therapeutic
laparotomy for pancreatic cancer
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is opened. These patients are exposed to the potential morbidity
associated with laparotomy without the benefit of resection.
When a non-therapeutic laparotomy has been performed, the
surgeon must decide whether or not to perform palliative or
pre-emptive bypass procedures. Some reports have suggested
that local extension of periampullary malignancies may result in
duodenal obstruction in 20–40% of cases.9,10 Biliary obstruction
is estimated to occur in 65–75% of patients, with resulting
pruritus, diarrhoea, cholangitis and potential hepatic failure.11
Although concomitant prophylactic duodenal and biliary
drainage at the time of non-therapeutic laparotomy was stan-
dard practice for many years,12 newer, less invasive means of
stenting luminal obstructions have augmented the palliative
armamentarium.
Both biliary and duodenal stents are associated with excellent
technical success rates equivalent to that achieved with operative
bypass, and are associated with quicker recovery and shorter
length of stay.12–14 This suggests that stents may be preferable to
operative bypass in selected patients. In addition, data from
MSKCC suggest that 97% of patients with unresectable periamp-
ullary cancer can be given successful endoluminal palliation of
their symptoms and never require reoperation.5 Despite advances
in stent design and improvements in stent patency, recurrent
obstructions are more frequent following stent placement, which
suggests that stents are not as durable and require more mainte-
nance than operative bypass.15,16 Thus, questions remain for
patients found to be unresectable at laparotomy: is it preferable to
defer operative bypass and plan to treat future problems endolu-
minally even if this means that several more procedures may be
required? Is it better to operatively prophylax at the time of lap-
arotomy with the hope of maximizing the purpose of the opera-
tion with one durable palliative procedure? Is a combination of
approaches indicated?
This study was conducted to investigate outcomes in a modern
population of patients who had undergone non-therapeutic lap-
arotomy at one institution during 2000–2009. Only patients who
had been followed at MSKCC until death were included. This
group was chosen because it enabled the capture of all postopera-
tive procedures and comprised 12% of patients brought to the
operating room for periampullary tumours during the study time
period. The study focused on profiling the frequency of invasive
procedures and the total number of hospital days accrued by
patients prior to death. These metrics were used as quantitative
surrogates for operative palliation.
Roughly half (46%) of all patients in this study required at
least one additional invasive procedure prior to death. The pro-
portions of patients requiring additional procedures were similar
regardless of the procedure performed at initial exploration
(range: 35–54%). No single operative strategy stood out as pre-
venting requirements for additional invasive procedures and the
number of in-hospital days did not differ amongst the various
procedures. Although no procedure emerged as clearly sup-
erior, some advantages unique to each operative strategy were
elucidated.
Patients who underwent gastrojejunostomy (duodenal or
double bypass) rarely (1%) needed a procedure to treat GOO,
Table 4 Postoperative characteristics in the study cohort
All patients Laparotomy
patients
Duodenal bypass
patients
Biliary bypass
patients
Double bypass
patients
(n = 157) (n = 33) (n = 17) (n = 47) (n = 60)
All procedures, n (%) 72 (46) 18 (55) 6 (35) 24 (51) 24 (40)
For biliary drainage, n 22 13 5 1 3
For GOO, n 24 10 0 13 1
Duodenal stents, n 17 9 0 7 1
Total in-hospital days, median 16 16 12 18 16
Complications, n (%) 44 (28) 7 (21) 2 (12) 11 (23) 24 (40)
Deaths, n 3 0 0 1 2
GOO, gastric outlet obstruction.
Table 5 Patient characteristics based on the presence of a preoperative biliary stent
No preoperative stent Preoperative stent
(n = 94) (n = 61)
Patients with preoperative jaundice, n 51 31
Patients with operative biliary drainage, n 64 43
Mean total bilirubin, mg/dl 5.8 2.7
Patients undergoing procedures for postoperative biliary obstruction, n 12 10
Patients undergoing procedures for postoperative complications, n 13 3
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whereas 29% of patients who did not undergo gastrojejunostomy
(laparotomy or biliary bypass) experienced a GOO that required
additional intervention. These data are similar to those published
in a study conducted at Johns Hopkins University9 in which 87
patients with unresectable periampullary cancer were randomized
to receive hepaticojejunostomy with or without prophylactic gas-
trojejunostomy. No patients treated with duodenal bypass expe-
rienced GOO, but 19% of patients in the no-gastrojejunostomy
arm required additional surgery for late GOO.
In the present review, patients with nausea and vomiting who
did not undergo gastrojejunostomy did not experience a higher
frequency of postoperative GOO (Table 2). However, these
patients numbered only five (3% of the whole study cohort) and
were probably selected not to have gastrojejunostomy because
other signs suggested their symptoms were not secondary to
GOO. The presence of nausea and vomiting has been shown by
others to be a reliable predictor of impending GOO in patients
with unresectable pancreatic cancer,17 and it is highly likely that
the omission of gastrojejunostomy in symptomatic patients in the
present cohort would have resulted in more endoscopic stenting
postoperatively.
In the present study, patients who underwent surgical biliary
drainage rarely (3%) required additional interventions for biliary
obstruction. In comparison, 36% of patients who did not undergo
a biliary bypass required additional procedures (either endoscopic
or radiologic) for biliary drainage. The present results following
surgical biliary drainage are similar to percentages reported by
others. In the largest randomized trial to compare outcomes in
operative biliary bypass with those in endoscopic biliary stenting
in the management of malignant biliary stricture, Smith et al.
reported a 2% incidence of recurrent biliary obstruction in the
operative arm.18 Shepherd et al.19 and Artifon et al.20 reported no
findings of recurrent obstruction following biliary bypass, but
patients in these trials had much shorter survival periods (124
days and 90 days, respectively) than patients in the present study
(328 days), which probably reflects the higher percentage of
distant disease in the former groups. In the present study, the 36%
incidence of postoperative biliary obstruction among patients
who did not have operative biliary bypass is lower than the
expected 75%, but this may be because approximately 40% of
these patients had been treated endoluminally prior to explora-
tion. Patients who underwent biliary bypass were more likely to
have elevated bilirubin at the time of exploration and, if this
procedure had not been performed, this would almost certainly
have required correction postoperatively.
These data demonstrate that patients rarely require interven-
tions for GOO following gastrojejunostomy, and rarely require
procedures for malignant biliary obstruction following surgical
biliary drainage. It could be inferred that the best procedure to
perform at operation would be a double bypass and this is indeed
commonly recommended. However, in this review, double bypass
patients were found to have undergone just as many postoperative
procedures and to have accrued just as many total hospital days as
any other group. Although some procedures avoided require-
ments for treating postoperative GOO and biliary obstruction,
this was counterbalanced by requirements for other procedures
for other postoperative complications. In addition, double bypass
patients experienced operative mortality (2%) that did not occur
in the laparotomy and duodenal bypass groups. Interestingly,
operative biliary drainage in the presence of a preoperative biliary
stent was associated with fewer procedures for postoperative com-
plications. The reason for this is not entirely clear, but it may
reflect the fact that a stented biliary tree is more thoroughly
drained and therefore yields fewer infectious complications. Find-
ings of improved outcomes when a palliative bypass operation is
performed in the setting of a stented biliary tree have been noted
by others.17
In the setting of jaundice or symptoms of duodenal obstruc-
tion, operative bypass was more likely to be performed and
patients who underwent a bypass operation experienced a rate
of postoperative re-intervention similar to that in patients who
underwent laparotomy alone. Although duodenal bypass and
biliary bypass almost completely obviated the need for interven-
tions for additional duodenal or biliary obstruction, the number
of procedures they prevented was offset by the procedures per-
formed for other complications that arose. In addition, a small
number of bypass patients experienced operative mortality. It is,
therefore, reasonable to individualize operative manoeuvres at
the time of non-therapeutic laparotomy according to the pre-
sence and severity of symptoms. Numerous other patient-specific
factors should be considered, including the patient’s overall health
and ability to tolerate complications, the patient’s access to
medical care, the cause of the patient’s unresectability (local vs.
metastatic disease), and the likelihood that the patient will return
to surgery for a second attempt at resection. In asymptomatic
patients, the surgeon should consider the patient’s access to
medical care and social support. If these are poor, then a more
durable gastrojejunostomy is reasonable. A biliary bypass may be
considered in an otherwise healthy patient with limited access to
medical care or in whom previous devices have failed. In other
contexts, laparotomy is a reasonable option. In the context of
impending GOO, gastrojejunostomy is most reasonable. In
patients with impending biliary obstruction, if a preoperative
stent is in place, a biliary bypass appears reasonable. In patients
without a preoperative stent, if the patient is otherwise healthy
and can tolerate potential associated complications, a biliary
bypass is reasonable.
These data suggest that, at the time of non-therapeutic laparo-
tomy, no operative strategy is clearly superior in terms of the
number of postoperative procedures and hospital days that might
be accrued. Therefore, an individualized approach using symp-
toms and other patient-related factors to guide surgical palliation
at the time of non-therapeutic laparotomy seems appropriate.
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